Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
20.55
-0.19 (-0.92%)
Nov 17, 2026, 2:35 PM EST - Market open
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

9M 2026 revenue grew 2%, adjusted EBITDA 6% and EPS 8%, with complex generics and China supporting momentum. Pacira and 2027 launches add growth potential, alongside H1 2027 cenerimod and 2027 selatogrel catalysts.

Ash Verma
Analyst, UBS

Great. Good day, everybody. Welcome to UBS Biopharma Conference in London. My name is Ash Verma. I cover SMID-cap Biotech and Spec Pharma, and I am really excited to have the Viatris team here today. Scott Smith, CEO, Paul Campbell, CFO, and Philippe Martin , Chief R&D Officer. Thank you guys so much for joining us. Maybe Scott, if you can give us a little bit of key points to, not that anybody needs a background about the story, but just hit some highlights on what are some of the key takeaways coming out of the third quarter earnings.

Scott Smith
CEO, Viatris

Well, thank you, Ash, and good morning to everybody, both on here in the room and on the webcast or audiocast or how we are doing this. We are really, really pleased with where we are and the momentum we have made in 2026. Just obviously last week had our, or first week of November, had our third quarter earnings call. Through three quarters of the year, from a financial perspective, I think we have made tremendous progress. We have got 2% revenue growth, and there has been a little bit of headwinds in terms of revenue, 6% EBITDA growth on a nine-month basis, which is last year, or sorry, 6% EBITDA growth and 8% EPS growth.

The strategy that we laid out of sort of mid-single digit, low single-digit revenue, mid-single digit EBITDA, and a little bit of EPS leverage because we are buying back shares, absolutely paying off financially. We see very, very good progress. I think it is a real turnaround start of sustainable growth going forward here, both in revenue and EBITDA and EPS. We are really excited about the performance of the company so far during the course of this year, through the first nine months. We also sort of strategically moved the portfolio in a very interesting way. More complex generics, transdermals, particularly in the HRT and contraceptives, doing very, very well. We have got complex respiratory drugs as well in the U.S.

W e see a movement in the U.S. away from sort of the simple oral solid dose generics into more complex generics, higher margin, more durable revenue. We have been really pleased with that. We see real progression in China, moving forward in China with some very strong performance in China, and that is higher margin business for us. We see launch of a number of products in Japan now to hopefully turn that around to being a real growth story. We are very, very excited about where we are financially, how we are developing the portfolio, and then later today, we should be able to close the acquisition of Pacira, bringing into the U.S. high-margin, innovative products in market growing.

We will take our promoted innovative U.S. position to over $1 billion in 2027. All that being said, very strong year in 2026. Good momentum going into 2027, both financially and with the portfolio. Then we have a couple of critical readouts in 2027 with cenerimod and selatogrel coming. We are very, very excited about where we are as a company and the setup for 2027 and beyond.

Ash Verma
Analyst, UBS

Great. Good start, and you hit a lot of key points, so that is great and a lot to unpack there. I guess, like on China, definitely, I mean, it has been a very interesting year for you, right? I mean, what an incredible, amazing growth that you have had. When you talked about it just on a go-forward basis here, so very strong comps to beat, right, like next year. How much of a focus has been to get good precision on what is the policy impact in China when you outline some of the growth dynamics?

Scott Smith
CEO, Viatris

Yeah. I think, first of all, I will say a couple words on China, and then you can go. There is a very strong market in China right now. For the first time ever in China, you see some dynamics where you have got a group of people retiring, elderly people who have disposable income that are interested in their healthcare. You see things like health club membership in China and other things going way up, right? Particularly for people, elderly, just early retired, and they are very interested in quality medication, right, as well. You see this generation of people who are willing to invest in their health, that are interested in real brand names, high-quality products.

The market is very strong. We have done a lot of investments in China. We have got a very good team there, very strong leadership. We have made investments in things like the e-commerce channel and other in China. We see our investments paying off there. We see really nice growth. We expect that to continue, not maybe at the pace that we saw this year. There is some policy implementation things going on, et cetera, but we see it being a growth story for us in 2027 and beyond. Paul, here.

Paul Campbell
CFO, Viatris

Thanks, Scott. I will just add to what Scott said. First half of the year, we had very, very strong year-over-year comp. We were up 16%, 17%. We said in Q2 that we expected that to moderate because of the policy change that happened. We did see that, 10% in Q3. We expect a little bit more in Q4, so maybe high single-digit growth. Then going into next year, we even see growth, but coming back to more low, mid-single-digit numbers, which is really amazing when you think about the comp now that they are going to have for 2026, in Q1 and Q2, and we still expect to be able to grow off of that. It will be a little bit less first half of the year, maybe a little bit more in the second half of the year.

As Scott said, the demographics really changed to the point where people, the cash-paying people, are willing to pay for brands that they really trust. Lipitor is one in particular that they really trust and they want to buy. Just a reminder, about 50% of our business is hospital, and the other 50% is between e-commerce and other retail channels. A couple years ago, we made a concerted effort, as Scott said, to really push to the cash paying and the retail channel as much as possible. Even within that 50% hospital, the government portion is around 50% or so.

The team over there has done an amazing job growing that. We do believe that the policy, even though it is not 100% set yet, that growth that I gave you, our expectation going to 2027 includes what we know today of all the impacts of that policy change.

Ash Verma
Analyst, UBS

Great. That is reassuring, because I have heard some investor questions around that, particularly after such a strong run, where are the expectations for next year, and that is very helpful. Maybe another part of the business that is sort of in early innings, the HRT market. That has been a big contributor for the developed markets. Just how do you think this market evolve, right? There are four key competitors, you are the biggest in this market, and we are seeing tremendous amount of growth. Going into next year and subsequent years, how do you think this would evolve from here?

Scott Smith
CEO, Viatris

Yeah, so I wouldn't say early innings, right? I mean, we've had a position here and we've had products. What you see is you see a real inflection in the marketplace having happened, right? From a strictly HRT perspective, you see this idea of the black box warnings around HRT being removed in the U.S., and that being real fuel for growth of the market. In terms of the transdermal market, you see also an accelerator, because of the high degree of utilization of GLP-1 products, which delay gastric emptying, and they have a tendency to break down hormones before they can become effective, and so the transdermal use of HRT has gone way up. The combination of the removal of the black box, the utilization of GLP-1s has really accelerated.

And we have a real opportunity here. We've been a player, and we're the largest player in this market from a generic perspective. All of us here in the room from Viatris have been to our facility in Vermont to see if there's excess capacity there. We've moved some things around, we've opened up a new packaging line. We're looking for alternate suppliers. We're looking to maybe build alternate transdermal manufacturing facilities. We really want to step in and try and meet this demand. I think it's very important. It's very important financially for the company. It's a great market. It's relatively high margin. There's tremendous growth there. But it's also important for patients, right?

And when there are these supplies, you see this real dynamic, I think, in the marketplace where women who are engaging in HRT that didn't before because of some of the warnings or concerns, are really find that they're having a positive experience with HRT, and they want to continue to get the patches. And so we want to be able, from a medical perspective, to be able to supply the market as well. We're working very, very hard on that.

Paul Campbell
CFO, Viatris

Yeah, just maybe to add a couple statistics behind it. I think IQVIA is up about 70% year over year. We said our volume basically doubled in the third quarter, so our market share is increasing. I get a lot of questions about competition, and from my perspective, at least as we see it right now, it is not so much competition, it is about meeting the market, as Scott said. The demand is growing so significantly, there is enough in the marketplace for whoever is out there competitor-wise. This is the time for us to invest. We are doing a lot of that right now, both internally and externally.

I think this year we did what we could do in the short term. We increased our production process from five by 24 to seven by 24 to get a little bit of growth that we got, and now we are investing to try to find third-party packagers for us, and then also put in a second packaging line so that we can continue to take advantage of the market.

Scott Smith
CEO, Viatris

Our particular, the patch, the transdermal device that we have, I think is very elegant, very thin, very small, not noticeable. It is a big advancement from the way the patch technology was even five, 10 years ago, and so it is a very elegant presentation as well.

Ash Verma
Analyst, UBS

Good. Yeah, I am looking forward to that. We have been tracking this data as well, so this is an exciting time to watch out how the space would evolve. Maybe just broadly speaking, just when you think about the 2027 dynamics, I know you are not providing guidance, but just in terms of some of the pushes and pulls, if you can talk about what are the growth opportunities that you see, any potential offsets that you think that would be sort of negative?

Scott Smith
CEO, Viatris

Yeah, I want Paul to be more specific relative to the pushes and pulls, but I see 2027 setting up like 2026. There is a lot of momentum. There definitely are some headwinds, particularly on the operations or supply side. There are some excellent tailwinds in terms of the transdermal HRT marketplace, in terms of the U.S. complex generics, in terms of China and other things. So, I see 2027 generally being sort of a continuation of the momentum that we have gotten in 2026, but do you want to go more specifically?

Paul Campbell
CFO, Viatris

Sure. Yeah, absolutely. We get a lot of questions about adjusted EBITDA, and of course, as Scott said, we are not providing guidance. But if you just look at the math, where midpoint of guidance in 2026 is $4.5 billion. We have Pacira coming in, hopefully full year. As Scott said, we close later today. We will have a full year worth next year. Then we have the new products like Gwyn Lo, what we call value-added, Gwyn Lo and meloxicam. We expect Gwyn Lo is launched. We expect meloxicam to launch. Just new product revenue that we normally would have, our $450 million-$550 million. We expect that, and then to offset erosion that we have.

We also have cost savings initiative that we put out there. We have a second year coming up, so we expect that growth momentum to happen. There are some headwinds also, LOE in isosorbide mononitrate in the U.S. We have a full year impact. We expect Amitiza could potentially go middle of the year, next year in Japan. And then we still have competition on some key products like Breyna and Wixela that continue, that we see on the horizon coming into the market. And then lastly, Nashik, we do not expect a recovery of that $200 million impact that we had in the second half of 2026 into 2027 right now.

We expect to ramp that production back up early next year so that we can, by the end of the year, be at full capacity, but we do not expect to recoup any of that 200. So you put that all together, I think the tailwinds outweigh the headwinds. We do have some headwinds, but we feel very good with the momentum going into 2027.

Ash Verma
Analyst, UBS

Great to hear that. Okay. So yeah, maybe I will switch gears to talking about business development. So this Pacira transaction, so this is an interesting opportunity that you have outlined. Can you talk about sort of the strategic rationale for what drove this? What is the growth opportunity that you see? How much durable are these franchises going to be?

Scott Smith
CEO, Viatris

Yeah, I think it is exactly what we communicated in the past, right? In-market accretive assets that have great growth potential we are acquiring, what this year is between $700 million and $800 million of U.S. revenue, again, to go. We have $300 million approximately in terms of Viatris and in terms of marketed, innovative, promoted products in the U.S., and then this adds another $700 million, $800 million going into next year. We see over $1 billion in this innovative promoted U.S. revenue. We believe there are two important assets there and a little bit of pipeline, but something that can definitely, assets that we believe we can put the right resources behind and grow them as we get into 2027 and beyond. And they are in an area that we are very interested in, right?

I think strategically, this helps provide some synergy, some positive synergy for our meloxicam launch, which we expect to have early in 2027, if approved on time and other things. So, I think having that infrastructure from a reimbursement, from an access, from a medical affairs perspective can really help accelerate the fast-acting meloxicam and meloxicam launch into 2027. So I think the combination of growing in-market accretive assets in the U.S., high margin, and then the capabilities that we are acquiring as well are very, very important. So, when I have talked to the Pacira group ahead of our closing, I have talked about this idea that it is not just the acquisition of assets, it is the acquisition of capabilities as well.

Given that, given our interest in non-opioid pain, given the fact that these are good in-market, high-margin accretive assets, it just seemed like that it fit us strategically very, very well.

Paul Campbell
CFO, Viatris

Maybe from a financial perspective, I would just add, it meets the criteria we laid out in March at our Investor Day, that we wanted to find assets over our five-year period, that we put out a target of between $1 billion and $1.5 billion in revenue, $500 million of adjusted EBITDA. This meaningfully puts us on that path to get there. Also, we did it in a very disciplined manner, right? We did not have really, we do not expect any impact on our leverage ratio as a result of this transaction. We have got enough cash and then a little bit of borrowing, but at the end of the day, very disciplined from a financial perspective, which is important.

Lastly, I think the multiple we paid for the business was very much in line with what we have put out as a target, right? It was like 9.3x based on the LTM period at June that we looked at. On a synergized basis, it's about 7.3%, which is right around our multiple, a little bit below what today's multiple is. Again, very disciplined from a financial perspective.

Ash Verma
Analyst, UBS

Does that fit the kind of the type of assets that we should expect going forward? In the past, you've done Idorsia, for example. When we think about the business development sort of strategy from here, is it early launch, late launch? This is kind of like a late mature launch opportunity, still growing a lot, or early stage clinical? Where does the BD focus sit within these three buckets?

Scott Smith
CEO, Viatris

I think this transaction fits exactly right in the middle of what we want to do, right? Again, in-market accretive, it's already launched, it's got, we can understand the trajectory, financially disciplined, the right kind of multiple. I think as we do BD, we're going to continue to do that, right? I think, so that's going to be the main focus of business development, things in market, likely U.S. focus, but with an opportunity to take them outside of the U.S. I think we also, not as a major business development thrust, but we also want to continue to add some pipeline, like in the Idorsia, in areas where we're building. But most of the BDs can be focused on in-market accretive things with U.S.-centric revenue that we can take internationally. I think that's what we're looking for. We want to continue to be disciplined.

As Paul said, we want to continue to be focused in acquiring things at the right price and the right multiple, and things that we think we can be good owners of. I think the Pacira transaction shows a couple of assets that we can be good owners of, and we'll continue to look for that kind of same kind of thing. We'll be disciplined. Again, in terms of capital allocation, right, we've talked about this idea of doing both business development and dividend and share buybacks, right? So 50/50 relatively equal between the two. I think we'll continue to be the same. We'll be disciplined from a capital allocation perspective. We're going to continue to buy back shares opportunistically, and we're going to continue to deliver the dividend.

W e are also going to look for nice opportunities, nice assets, nice companies that we can bring into Viatris.

Ash Verma
Analyst, UBS

In terms of the synergy target that you have outlined for this, so the roughly $50 million, sorry, that is around 10% of the cost base that Pacira has had. Is this because that you are using effectively this as a way of also sort of expanding your commercial footprint to fuel the oral meloxicam launch?

Scott Smith
CEO, Viatris

Yes. Right. I mean, we are acquiring capabilities, right? And not just assets, but capabilities. There are some back office things that we can get synergies of. I think we have put out at least $50 million in terms of synergies. And again, it is not a deal that we were doing for synergies. It was a deal we were doing for assets and capabilities. But I do not know if you want to

Paul Campbell
CFO, Viatris

Yeah, absolutely. What we identified early on are those duplicates of the costs, back office costs, right? Eliminating some of the public company costs, those kind of things. I think as we get in and we start the integration planning, that we will find more opportunity. That is our expectation right now. We will look across the landscape and see what is there. But to Scott's point, we did not do the transaction specifically for synergies. We got the capabilities from a commercial perspective. The last thing I would say is, we have not quantified out there what the synergy with meloxicam would be, but we do expect that as a result of this additional hospital channel that we will have available to us now, that we can kind of jumpstart that launch and really get the momentum we need for the next few years.

Ash Verma
Analyst, UBS

Great. Wonderful. All right. Philippe , maybe just coming to you, talk about all the pipeline, right? I mentioned cenerimod for SLE lupus. This is generally like a very difficult indication, as you know, but you have some supportive data here, big catalyst coming up in the first half of 2027. I guess I will ask a couple of quick specific questions. I think one of the things that we have seen is that the prior phase II, you had efficacy until six months, and then there was like a post-hoc analysis that you showed efficacy build-up over 12 months. I think one of the things that is a focus for investors right now is that the phase III goes out to 12 months, right? So what type of evidence, confidence do you have that that efficacy would build over time?

There is a Japanese study as well, which I am familiar with, but that is very small number of patients. Just if you can sort of like talk about how the mechanism would ensure that there is cumulative efficacy build.

Philippe Martin
Chief R&D Officer, Viatris

Sure. Let me just remind you, the phase II study CARE phase II-B study, after six months, the 4 mg dose was switched to 2 mg , right? That was the design at the time. In phase III, we are going to keep 4 mg all the way to 12 months. I think when you look at the phase II CARE data, what you see is that the efficacy at six months has not reached its peak, right? You continue to see further differentiation at eight months, even though you have switched to 2 mg , right, at that point. We certainly, that combined with the Japanese data that you mentioned, granted small sample size, but what you see is that the 4 mg continues to improve over time all the way to 12 months.

Put that together with the biological evidence that the mechanism of action of the drug and the half-life of the drug that is relatively long, this supports a long-term efficacy over 12 months. Again, at eight months or so in phase II CARE, you see further improvement than you saw at six months, which was the primary endpoint of the study at six months. Then 12 months is also important because, first, it is a regulatory expectation in lupus that you would be able to demonstrate the benefit risk of the drug at 12 months. It also allows you to do other things with the design that we were not able to do in phase II, including your forced corticosteroid tapering, that typically leads to better separation at week 52 versus placebo plus standard of care.

That together with the data bodes well for cenerimod. I would also add that in the phase II study, the entry criteria were not as stringent as in phase III. That led to about 30% of the population not being active, which makes it very difficult to separate from placebo in lupus. In phase III, we have installed entry criteria that will lead to a population that is a lot more active, interferon-1 high patients, but also patient with a BILAG 1A or 2B. That was not the case in phase II. Overall, a much more active population, where we saw the best results in phase II, and the phase III trial is enriched for that population. We feel good about the probability of success of this asset at this point.

Scott Smith
CEO, Viatris

Can I brag on Philippe for a second?

Ash Verma
Analyst, UBS

Do it.

Scott Smith
CEO, Viatris

I think Philippe has incredible experience in the immunology space, right? He was a lead developer of Otezla, a lead developer around ozanimod, and involved both in the IBD and MS indications for ozanimod, which is an S1P molecule as well. I think there is no more capable person in the world to handle the development of this asset than Philippe, so we are thrilled to have him.

Philippe Martin
Chief R&D Officer, Viatris

Thanks.

Ash Verma
Analyst, UBS

Right. Yeah. It takes the steroid tapering that you talked about. Can you elaborate on that? What effectively is the goal there? Yeah, we have seen some data that it can help with the flare rates, right? But is there tangible evidence that it can help with the primary endpoint?

Philippe Martin
Chief R&D Officer, Viatris

Yeah. I think, first of all, the reason why we are doing corticosteroid tapering is because it is a treatment goal in SLE, right? What you want to be able to do is to reduce the steroid dose, but avoid having the patient flare. If your drug is able to maintain efficacy over time, you will be able to reduce that corticosteroid but keep the patients from flaring, right? If you do that with a placebo patient or patient on standard of care, you will see patients flaring, and that will lead to less responder on the placebo arm than on the treatment arm. There is some data out there that shows that it is about, can help about 10%, right? Typically. I think it is difficult to put a number to it. There are other factors that come into play.

As I said, I think how active your patient population is has a meaningful impact on your ability to separate from placebo. It is a combination of things, but I think it is important, as opposed to phase II, where we are not able to do that, to be able to implement that in phase III. That will help us further separate from placebo. You should expect in phase III a placebo rate around 40%. It can go 45%, it can go 35%. But on average, I would say about a 40% placebo response rate is what one would expect in phase III. Phase II, typically, you see lower placebo rates because patient population is smaller, it is better controlled, and so on and so forth. But in phase III, I would say 40%, 45% is what one should expect.

Ash Verma
Analyst, UBS

Got it. Okay. All right. Selatogrel, can you just briefly touch on why choose the endpoint that you chose instead of just effectively looking at MACE reduction?

Philippe Martin
Chief R&D Officer, Viatris

Right. Selatogrel, we are looking for something a little bit different than what you would typically look for with a traditional MACE endpoint. We are looking at how early, if you are able to give selatogrel very early, does that lead to, one, less MI, but two, less severe MI as well? That is particularly important. You have to design an endpoint that is allowing you to be able to determine that. A ranked endpoint like we have put together allows you to go after that difference in the severity of the MI. You start by ranking what is most important, which is the most severe case, death in this case, but then you rank also by severity of the various MI you are going to see.

It makes for a very effective endpoint from a statistical standpoint for what we are looking for here. It is a better-suited endpoint to look at reduction in severity of MI with selatogrel versus placebo.

Ash Verma
Analyst, UBS

Great. Awesome. Thanks for that. And looking forward to the data. All right, just like final question. I mean, I think the stock has done really well over the last one year, and sometimes, I always get this question like, "Did I miss it already?" From investor standpoint. So the way that, like, how would you frame sort of the upside in the story, either the base business or pipeline? Where can things go from here?

Scott Smith
CEO, Viatris

I think you had a baseball analogy earlier where you said we're in the early innings, right? I think we're in the early innings of where we need to go or where we can get with Viatris, right? I think we've done a lot of work to get the company where it is today. We paid down debt. We've done some things. We've pruned the company. We've done the cost-saving measures. We've added important assets to the pipeline. We're doing acquisitions. We're deploying our capital. And I think the most important thing, I think, overall for the company that shows the health of the company is how well the base business is doing, how much we see places like, how well we see China doing, how well we see the U.S. doing, how we see the evolution of the generic portfolio away from OSD and towards complex generics.

And so, that base business doing so well right now, really good people, the cost measures we put in place, the things we have, and the launches we have in the next couple years. And then, of course, you get selatogrel and cenerimod, which would be tremendous growth drivers for us 2030 and beyond. I think we're just sort of starting out right now in terms of this is the beginning of where we can get. And being Canadian myself, whenever I go up to Canada, all the investors say to me that I know up there, "Do we miss this?" And I'm like, "You're right at the very beginning of where we hope to take this company." And so, I don't think people have missed anything.

The company is healthier now than it was a couple years ago, and I expect the company to be even healthier in a couple years than it is today.

Paul Campbell
CFO, Viatris

Yeah. That just add, I think because of where our multiple is, we still feel we're undervalued even at the stock price we're at. We're still below most of our peers, and we expect there to be additional runway in the future.

Ash Verma
Analyst, UBS

Awesome. Great. With that, we can wrap it up. Thank you so much for your time.

Scott Smith
CEO, Viatris

Thank you, Ash.

Paul Campbell
CFO, Viatris

Thank you.

Philippe Martin
Chief R&D Officer, Viatris

Thank you.